For anyone in Tsáda searching for CJC-1295, the foundational reality is that this compound is available only through an online research supply market. What this means for Tsáda researchers is that your location matters far less than your ability to assess COA data — and those quality checks are available to every researcher. A credible CJC-1295 supplier's COA needs to show HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all traceable to your specific batch. This guide gives Tsáda researchers the practical tools to verify sourcing options methodically and source research-grade CJC-1295 with confidence.
What Studies Say About CJC-1295
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Tsáda comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
CJC-1295 Purchasing Guide
Before assessing any particular supplier, establish a quality benchmark — so you can identify whether a supplier meets the standard. Mass spectrometry in the COA establishes that the main HPLC peak is actually CJC-1295 and not another compound with similar chromatographic behaviour — HPLC purity alone provides no identity confirmation. Strong quality indicators beyond COA quality: multi-year operating history, customer service that can discuss analytical methods, and temperature-appropriate packaging with desiccant. Price is an ineffective primary criterion for CJC-1295 quality — research-grade synthesis and testing has genuine production costs that cannot be cut without consequences, so the lowest-priced options almost always involve trade-offs.
Order CJC-1295 — ships to Tsáda
COA-verified · International tracking · Research grade
All use of CJC-1295 in Tsáda or anywhere must be research use only — this compound is not approved for clinical human use, and all handling should comply with standard research safety practices. Proper handling of CJC-1295 requires sterile reconstitution technique — alcohol-swabbed septum, fresh needles, clean working environment — and cold chain maintenance from receipt through use. Quality CJC-1295 sourcing is inseparable from safety — bacterial endotoxin contamination, wrong peptide identity, and degraded material are all safety issues that rigorous vendor evaluation eliminates. The research literature on CJC-1295 should be read critically before designing any protocol — study methodologies, dosing, and endpoints vary significantly and not all findings translate directly.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
